Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2001-11-01
2010-06-22
Weber, Jon P (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S007230
Reexamination Certificate
active
07741019
ABSTRACT:
A method for the diagnosis, prognosis, and monitoring of ovarian cancer in a subject by detecting hK10 in a sample from the subject, preferably a serum sample or tumor tissue extract. hK10 may be measured using a reagent that detects or binds to hK10 preferably antibodies specifically reactive with hK10 or a part thereof. Imaging methods for tumors associated with hK10 are also described using an agent that binds to hK10 which had a label for imaging the tumor.
REFERENCES:
patent: 4921790 (1990-05-01), O'Brien
patent: 5736377 (1998-04-01), Band
patent: 5843694 (1998-12-01), Band
patent: 6962793 (2005-11-01), Diamandis
patent: 7022497 (2006-04-01), Yousef et al.
patent: 7504214 (2009-03-01), Erlander et al.
patent: 2003/0108963 (2003-06-01), Schlegel et al.
patent: 2004/0058342 (2004-03-01), Diamandis
patent: 2004/0096915 (2004-05-01), Diamandis
patent: 2004/0203012 (2004-10-01), Diamandis
patent: 2005/0106586 (2005-05-01), Diamandis
patent: 2005/0176002 (2005-08-01), Diamandis
patent: 2005/0287528 (2005-12-01), Diamandis
patent: 2006/0073525 (2006-04-01), Yousef
patent: 2006/0078941 (2006-04-01), Santin
patent: 2006/0134114 (2006-06-01), Yousef
patent: 2006/0134120 (2006-06-01), Diamandis
patent: 2006/0141471 (2006-06-01), Diamandis
patent: 2006/0159616 (2006-07-01), Diamandis
patent: 2006/0223059 (2006-10-01), Yousef
patent: 2006/0269971 (2006-11-01), Diamandis
patent: 2007/0212721 (2007-09-01), Fischer et al.
patent: 98/20117 (1998-05-01), None
patent: WO-00/53776 (2000-09-01), None
patent: WO-02/14485 (2002-02-01), None
patent: WO-02/35232 (2002-05-01), None
patent: WO-02/37112 (2002-05-01), None
patent: WO-02/097438 (2002-12-01), None
patent: WO-03/033731 (2003-04-01), None
patent: WO 2005/118840 (2005-12-01), None
Berek et al, “Ovarian Cancer Screening: The Use of Serial Complementary Tumor Markers to Improve Sensitivity and Specificity for early Detection”, Cancer (1995); 76:2092-2096.
Bjartell et al, The Histochemical Journal 1999, vol. 31, p. 45-52.
Badgwell et al, Disease Markers, 2007, vol. 23, No. 5-6, pp. 397-410, abstract only.
Zhang et al., Gynecologic Oncology, 2007, vol. 107, pp. 526-531.
Visintin et al., Clinical Cancer Research, 2008, vol. 14, No. 4, pp. 1065-1072.
Badgwell et al., “Early Detection of Ovarian Cancer”, Disease Markers, 2007, vol. 23, No. 5-6, pp. 397-410.
Aznavoorian et al., “Molecular Aspects of Tumor Cell Invasion and Metastasis”, Cancer (1993); 71: 1368-1383.
Berek et al., “Ovarian Cancer Screening: The Use of Serial Complementary Tumor Markers To Improve Sensitivity and Specificity for Early Detection”, Cancer (1995); 76: 2092-2096.
Bhoola et al., “Bioregulation of Kinins: Kallikreins, Kininogens, and Kininases”, Pharmacological Reviews (1992); 44: 1-80.
Burger et al., “Inhibin and ovarian cancer”, Journal of Reproductive Immunology (1998); 39: 77-87.
Chu, “Prostate-Specific Antigen and Early Detection of Prostate Cancer”, Tumor Biology (1997); 18: 123-134.
Clements, “The Molecular Biology of the Kallikreins and their Roles in Inflammation”, In: Farmer SG (ed) The Kinin System, Academic Press (1997); 5: 71-97.
Daidone et al., “Laminin Receptors, Collagenase IV and Prognosis in Node-Negative Breast Cancers”, International Journal of Cancer (1991); 48: 529-532.
Diamandis et al., “The New Human Kallikrein Gene Family: Implications in Cacinogenesis”, Trends in Endocrinology and Metabolism (2000); 11: 54-60.
Duffy et al., “Urokinase-Plasminogen Activator, a New and Independent Prognostic Marker in Breast Cancer”, Cancer Research (1990); 50: 6827-6829.
Duffy, “ The role of Proteolytic enzymes in cancer invasion and metastasis”, Clinical and Experimental Metastasis (1992); 10: 145-155.
Foekens et al., “Prognostic Value of Urokinase-type Plasminogen Activator in 671 Primary Breast Cancer Patients”, Cancer Research (1992); 52: 6101-6105.
Goyal et al., “The Role for NES1 Serine Protease as a Novel Tumor Suppressor”, Cancer Research (1998); 58: 4782-4786.
Lambert-Messerlian, “Is inhibin a serum marker for ovarian cancer?”, European Journal of Endocrinology (2000); 142:331-333.
Liu et al., “Identification of a Novel Serine Protease-like Gene, the Expression of Which Is Down-Regulated during Breast Cancer Progression”, Cancer Research (1996); 56: 3371-3379.
Luo et al., “Structural Characterization and Mapping of the Normal Epithelial Cell-Specific 1 Gene”, Biochemical and Biophysical Research Communications (1998); 247: 580-586.
McCormack et al., “Molecular Forms of Prostate-Specific Antigen and the Human Kallikrein Gene Family: A New Era”, Urology (1995); 45: 729-744.
Pisani et al., “Estimates of the Worldwide Mortality From Eighteen Major Cancers in 1985. Implications for Prevention and Projections of Future Burden”, International Journal of Cancer (1993); 55: 891-903.
Riegman et al., “Characterization of the Human Kallikrein Locus”, Genomics (1992); 14: 6-11.
Riman et al., “Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence”, Clinical Endocrinology (1998); 49: 695-707.
Rittenhouse et al., “Human Kallikrein 2 (hK2) and Prostate-Specific Antigen (PSA): Two Closely Related, But Distinct, Kallikreins in the Prostate”, Critical Reviews in Clinical Laboratory Sciences (1998); 35: 275-368.
Stenman, “New Ultrasensitive Assays Facilitate Studies on the Role of Human Glandular Kallikrein (hK2) as a Marker for Prostatic Disease”, Clinical Chemistry (1999); 45: 753-754.
Thorpe et al., “Association between High Concentrations of Mr52,000 Cathepsin D and Poor Prognosis in Primary Human Breast Cancer”, Cancer Research (1989); 49: 6008-6014.
Xu et al., “OVXI Radioimmunoassay Complements CA-125 for Predicting the Presence of Residual Ovarian Carcinoma at Second-Look Surgical Surveillance Procedures”, Journal of Clinical Oncology (1993); 11: 1506-1510.
Luc et al., “The Normal Epithelial Cell-Specific 1 (NES1) Gene is Up-Regulated by Steroid Hormones in the Breast Carcinoma Cell Line BT-474”, Anticancer Research (2000); 20: 981-986.
Luo et al., “Expression of the normal epithelial cell-specific 1 (NESI; KLK 10) candidate tumour suppressor gene in normal and malignant testicular tissue”, British Journal of Cancer (2001); 85(2): 220-224.
Bharaj et al., “Identification of Single Nucleotide Polymorphisms in the Human Kallikrein 10 (KLK10) Gene and Their Association with Prostate, Breast, Testicular and Ovarian Cancers” The Prostate, 51:35-41 (Apr. 1, 2002).
Dhar et al, “Analysis of Normal Epithelial cell Specific-1 (NEW1)/Kallikrein 10 mRNA Expression by in Situ Hybridization, a Novel Marker for Breast Cancer”, Clin. Cancer Res., 7:3393-3398 (Nov. 2001).
Luo et al, “Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance”, Brit. J. Cancer, 86(11):1790-1796 (Jun. 5, 2002).
Petraki et al, “Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues”, Prostate Cancer and Prostatic Dis., 6:223-227 (2003).
Luo et al, “Prognostic Value of Human Kallikrein 10 Expression in Epithelial Ovarian Carcinoma”, Clin. Cancer Res., 7:2372-2379 (Aug. 2001).
Luo et al, “Human Kallikrein 10: A novel tumor marker for ovarian carcinoma?”, Clin. Chim. Acta 306:111-118 (Apr. 2001).
Sidiropoulos, M., et al., Downregulation of Human Kallikrein 10 (KLK10/NES1) by CpG Island Hypermethylation in Breast, Ovarian and Prostate Cancers, Tumor Biology, vol. 26, (Oct. 26, 2005), pp. 324-336.
Santin, A, et al., Overexpression of Kallikrein 10 (hK10) in Uterine Serous Papillary Carcinomas, American J. Obstetrics and Gynecology, vol. 194, (Oct. 2005), pp. 1269-1302.
Ruckert, F., et al., Co-expression of KLK6 and KLK10 as Prognostic Factor
Diamandis Eleftherios P.
Luo Liu-Ying
Howson & Howson LLP
Mount Sinai Hospital
Schuberg Laura
Weber Jon P
LandOfFree
Detection of ovarian cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection of ovarian cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of ovarian cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181253